GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Vicarious Surgical Inc (NYSE:RBOT) » Definitions » ROE %

Vicarious Surgical (Vicarious Surgical) ROE % : -74.74% (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Vicarious Surgical ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Vicarious Surgical's annualized net income for the quarter that ended in Mar. 2024 was $-68.00 Mil. Vicarious Surgical's average Total Stockholders Equity over the quarter that ended in Mar. 2024 was $90.99 Mil. Therefore, Vicarious Surgical's annualized ROE % for the quarter that ended in Mar. 2024 was -74.74%.

The historical rank and industry rank for Vicarious Surgical's ROE % or its related term are showing as below:

RBOT' s ROE % Range Over the Past 10 Years
Min: -76.4   Med: -69.23   Max: 5.31
Current: -67.45

During the past 4 years, Vicarious Surgical's highest ROE % was 5.31%. The lowest was -76.40%. And the median was -69.23%.

RBOT's ROE % is ranked worse than
82.24% of 805 companies
in the Medical Devices & Instruments industry
Industry Median: 0.17 vs RBOT: -67.45

Vicarious Surgical ROE % Historical Data

The historical data trend for Vicarious Surgical's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vicarious Surgical ROE % Chart

Vicarious Surgical Annual Data
Trend Dec20 Dec21 Dec22 Dec23
ROE %
-76.40 -70.45 5.31 -68.01

Vicarious Surgical Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -108.35 -75.07 -68.44 -50.96 -74.74

Competitive Comparison of Vicarious Surgical's ROE %

For the Medical Devices subindustry, Vicarious Surgical's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vicarious Surgical's ROE % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Vicarious Surgical's ROE % distribution charts can be found below:

* The bar in red indicates where Vicarious Surgical's ROE % falls into.



Vicarious Surgical ROE % Calculation

Vicarious Surgical's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-71.071/( (111.045+97.969)/ 2 )
=-71.071/104.507
=-68.01 %

Vicarious Surgical's annualized ROE % for the quarter that ended in Mar. 2024 is calculated as

ROE %=Net Income (Q: Mar. 2024 )/( (Total Stockholders Equity (Q: Dec. 2023 )+Total Stockholders Equity (Q: Mar. 2024 ))/ count )
=-68.004/( (97.969+84.01)/ 2 )
=-68.004/90.9895
=-74.74 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2024) net income data. ROE % is displayed in the 30-year financial page.


Vicarious Surgical  (NYSE:RBOT) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-68.004/90.9895
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-68.004 / 0)*(0 / 112.575)*(112.575 / 90.9895)
=Net Margin %*Asset Turnover*Equity Multiplier
=N/A %*0*1.2372
=ROA %*Equity Multiplier
=N/A %*1.2372
=-74.74 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-68.004/90.9895
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-68.004 / -68.004) * (-68.004 / -64.436) * (-64.436 / 0) * (0 / 112.575) * (112.575 / 90.9895)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 1.0554 * N/A % * 0 * 1.2372
=-74.74 %

Note: The net income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Vicarious Surgical ROE % Related Terms

Thank you for viewing the detailed overview of Vicarious Surgical's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Vicarious Surgical (Vicarious Surgical) Business Description

Traded in Other Exchanges
N/A
Address
78 Fourth Avenue, Waltham, MA, USA, 02451
Vicarious Surgical Inc designs a surgical robot that enables surgeons to perform minimally invasive surgery with 3D visualization and accurate control. Its Vicarious Surgical Robotic System is designed with a focus on abdominal access and visualization through a single port.
Executives
William John Kelly officer: CFO and Treasurer C/O VICARIOUS SURGICAL INC., 78 4TH AVENUE, WALTHAM MA 02451
Adam David Sachs director, 10 percent owner, officer: President and CEO C/O VICARIOUS SURGICAL INC., 78 4TH AVENUE, WALTHAM MA 02451
Sammy Khalifa director, 10 percent owner, officer: Chief Technology Officer C/O VICARIOUS SURGICAL INC., 78 4TH AVENUE, WALTHAM MA 02451
June Morris officer: CLO, General Counsel and Sec C/O VICARIOUS SURGICAL INC., 78 4TH AVENUE, WALTHAM MA 02451
John Mazzola officer: Chief Operating Officer TRANSMEDICS INC, 200 MINUTEMAN ROAD, ANDOVER MA 01810
Khosla Ventures Opportunity Associates Ii, Llc 10 percent owner 2128 SAND HILL ROAD, MENLO PARK CA 94025
Khosla Ventures V, L.p. 10 percent owner 2128 SAND HILL ROAD, MENLO PARK CA 94025
Khosla Ventures Opportunity Ii, L.p. 10 percent owner 2128 SAND HILL ROAD, MENLO PARK CA 94025
David D Ho director UNIT 1008, 10/F, CHAMPION TOWER, 3 GARDEN ROAD, CENTRAL K3 00000
Philip Liang director C/O VICARIOUS SURGICAL INC., 78 4TH AVENUE, WALTHAM MA 02451
Brendel Victoria Carr director C/O VICARIOUS SURGICAL, INC., 78 FOURTH AVENUE, WALTHAM MA 02451
Beverly A Huss director C/O ACCURAY INCORPORATED, 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
E15 Fund Ii, Lp other: Sole Shareholder C/O VICARIOUS SURGICAL INC., 78 4TH AVENUE, WALTHAM MA 02451
Shrikant Patnaik other: Principal C/O VICARIOUS SURGICAL INC., 78 4TH AVENUE, WALTHAM MA 02451
Ric Fulop director C/O DESKTOP METAL, INC., 63 THIRD AVENUE, BURLINGTON MA 01803